Electromed, Inc. (ELMD)

Electromed, Inc. announced record financial performance in its fiscal 2026 second quarter in February 2026, with increased net revenues and net income. The company authorized a share repurchase program, with $2.8 million in common stock repurchased in Q2 FY2026 and $3.8 million over six months. A $10 million share repurchase authorization was approved by the board in September 2025. The company also reported record fiscal 2025 fourth quarter and full year financial results in August 2025, marking its eleventh consecutive quarter of year-over-year revenue and operating income growth. In June 2025, Electromed was added to the Russell 2000® and Russell 3000® indexes. Over the past 12 months, the stock has gained 6.5%. However, it has also seen a significant decline from a peak of $35.43 to approximately $18, before recovering to around $23-$24 per share as of early April 2026.

Information regarding specific demand seasonality for Electromed, Inc.'s products and services is not explicitly detailed in the provided search results.

Electromed, Inc. is a medical device company specializing in airway clearance therapy products, operating in the Healthcare Equipment & Supplies industry. Their primary mission is to provide innovative airway clearance therapy for patients to manage their respiratory health at home. The flagship product is the SmartVest® Airway Clearance System, which utilizes High Frequency Chest Wall Oscillation (HFCWO) therapy. The SmartVest system is designed for patients with compromised pulmonary functions, such as bronchiectasis, cystic fibrosis, and neuromuscular conditions. Other major products include the SmartVest SQL System, SmartVest Clearway System, and SmartVest Connect, a wireless technology for therapy management. The company also offers single patient use SmartVest and SmartVest Wrap products for acute care settings.

Electromed, Inc. markets its products to physicians, healthcare providers, and directly to patients in the United States and internationally. The company is headquartered in New Prague, Minnesota.

Electromed, Inc. generally maintains a positive brand reputation, recognized as a leader in airway clearance technologies. The company is known for its innovative SmartVest® Airway Clearance System, designed for patient comfort and ease of use. Its direct-to-patient and provider model, which manages insurance claims, product delivery, and training, is highlighted as a key differentiator and contributes to high gross margins and profitability. Some potential challenges include margin compression, increasing competitive pressures, and questions regarding the comparative efficacy of HFCWO versus alternative therapies.

Electromed, Inc. has a mixed ownership structure, including institutional, retail, and individual investors. As of early April 2026, institutional investors hold approximately 35.27% of the company's stock, while insiders hold about 7.21%, and public companies and individual investors own roughly 57.52%. Major institutional owners include J.E. Simmons & Co., P.C., Vanguard Group Inc, BlackRock, Inc., Acadian Asset Management Llc, Geode Capital Management, Llc, Punch & Associates Investment Management, Inc., Dimensional Fund Advisors Lp, Renaissance Technologies Llc, Gamco Investors, Inc. Et Al, and Two Sigma Advisers, Lp. Key individual and insider owners include Red Oak Partners LLC, George H. Winn, Thomas M. Hagedorn, Stephen H. Craney, Robert D. Hansen, Noel D. Collis, Andrew Summers, and Craig N. Hansen.